Gene Therapy for Crigler-Najjar Syndrome Demonstrates Long-Term Effectiveness

A study published in The New England Journal of Medicine reports sustained efficacy of AAV8-mediated gene therapy (GNT0003) for Crigler-Najjar syndrome four years after treatment. This clinical trial, sponsored by Généthon, offers a promising new therapeutic avenue for correcting genetic liver diseases. The long-term data is crucial for validating the therapy's potential.